Difference between revisions of "Talk:Non-small cell lung cancer"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to record, in reverse chronological order, conversations about content changes for the accompanying main page. ==Ap...") |
m (→April 2018) |
||
| Line 2: | Line 2: | ||
==April 2018== | ==April 2018== | ||
| + | *[[User:Jwarner]] to [[User:Travisosterman]]: I’ve been shying away from adding randomized phase II’s to HemOnc.org but [https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.30986 this one] caught my eye. We don’t have have carbo-pem-bev under the “elderly or poor performance status” section – would you like to add it? | ||
*[[User:Travisosterman]]: I'm not sure if you saw the [http://investors.merck.com/news/press-release-details/2018/KEYTRUDA-pembrolizumab-Monotherapy-Met-Primary-Endpoint-in-Phase-3-KEYNOTE-042-Study-Significantly-Improving-OS-as-First-Line-Therapy-in-Locally-Advanced-or-Metastatic-NSCLC-Patients-Expressing-PD-L1-in-at-Least-1-Percent-of-Tumor-Cells/default.aspx press release]. Do you usually wait for FDA approval before posting 1st line regimen changes? This will change practice in the community pretty quickly for stage IV nsclc. | *[[User:Travisosterman]]: I'm not sure if you saw the [http://investors.merck.com/news/press-release-details/2018/KEYTRUDA-pembrolizumab-Monotherapy-Met-Primary-Endpoint-in-Phase-3-KEYNOTE-042-Study-Significantly-Improving-OS-as-First-Line-Therapy-in-Locally-Advanced-or-Metastatic-NSCLC-Patients-Expressing-PD-L1-in-at-Least-1-Percent-of-Tumor-Cells/default.aspx press release]. Do you usually wait for FDA approval before posting 1st line regimen changes? This will change practice in the community pretty quickly for stage IV nsclc. | ||
**[[User:Jwarner]]: KEYNOTE-042 added, using the 2015 ASCO abstract while we await newer data to be published | **[[User:Jwarner]]: KEYNOTE-042 added, using the 2015 ASCO abstract while we await newer data to be published | ||
Revision as of 16:09, 22 April 2018
The purpose of this page is to record, in reverse chronological order, conversations about content changes for the accompanying main page.
April 2018
- User:Jwarner to User:Travisosterman: I’ve been shying away from adding randomized phase II’s to HemOnc.org but this one caught my eye. We don’t have have carbo-pem-bev under the “elderly or poor performance status” section – would you like to add it?
- User:Travisosterman: I'm not sure if you saw the press release. Do you usually wait for FDA approval before posting 1st line regimen changes? This will change practice in the community pretty quickly for stage IV nsclc.
- User:Jwarner: KEYNOTE-042 added, using the 2015 ASCO abstract while we await newer data to be published